67384
document
Rioprostil , a new prostaglandin E1 analogue , in the once-daily treatment for the prevention of duodenal ulcer recurrence : a comparison with ranitidine . The efficacy of Rioprostil ( a new prostaglandin E1 analogue ) is compared with that of ranitidine in the recurrence prevention of duodenal ulcer ( s ) . Duration of treatment is 6 months . Ninety-seven patients received rioprostil , 600 micrograms once-daily orally , and 110 patients received ranitidine , 150 mg once-daily orally . On rioprostil , 14.9 % of patients showed a relapse after 6 months compared to 10.1 % on ranitidine . Diarrhoea occurred in 7 patients on rioprostil and 3 patients on ranitidine . Rioprostil given 600 micrograms daily in the evening is a highly effective treatment for the prevention of duodenal ulcer relapse , the efficacy not being significantly different from ranitidine 150 mg .
67385
Intervention_Pharmacological
Rioprostil
67386
Intervention_Pharmacological
Rioprostil
67387
Intervention_Pharmacological
ranitidine
67388
Intervention_Pharmacological
rioprostil , 600 micrograms once-daily orally
67389
Intervention_Pharmacological
ranitidine , 150 mg once-daily orally
67390
Intervention_Pharmacological
rioprostil
67391
Intervention_Pharmacological
ranitidine
67392
Intervention_Pharmacological
rioprostil
67393
Intervention_Pharmacological
ranitidine
67394
Intervention_Pharmacological
Rioprostil
67395
Intervention_Pharmacological
ranitidine
67396
Outcome_Other
efficacy
67397
Outcome_Physical
relapse
67398
Outcome_Adverse-effects
Diarrhoea
67399
Outcome_Physical
efficacy
67400
Participant_Condition
duodenal ulcer
67401
Participant_Sample-size
Ninety-seven
67402
Participant_Sample-size
110